**Secondary Endpoints**

At week 8, roflumilast foam 0.3% achieved a Body IGA (B-IGA) success rate of 40.3% compared to a vehicle rate of 6.8% (p < 0.0001). Roflumilast foam 0.3% achieved a SI-NRS 4-pt response in 71.0% of patients compared to a vehicle rate of 18.5% (p < 0.0001) at week 8.***

**TOPLINE STUDY RESULTS**

Once-daily roflumilast foams demonstrated statistically significant improvement over the vehicle foam in all the trial’s primary endpoints and met multiple secondary endpoints in patients with plaque psoriasis that includes plaques on the scalp.

**Primary Endpoint**

At week 8, roflumilast foam 0.3% achieved a Scalp Investigator Global Assessment Scale (S-IGA) success rate of 59.1% compared to a vehicle rate of 11.4% (p < 0.0001).

These positive results highlight the potential of roflumilast once-daily foam as a safe, convenient topical treatment option for chronic use that is appropriate for application on all areas of the body, particularly hair-bearing areas, such as the scalp, where a cream, lotion, or ointment is not suitable.

**Safety**

Key Takeaway

Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile.

Roflumilast foam was well-tolerated, with low rates of adverse events, treatment-related adverse events, and discontinuations due to adverse events. All rates were similar to vehicle.

For more information, visit www.ClinicalTrials.gov, Identifier: NCT04128007.